Squarepoint’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-34,600
| Closed | -$1.19M | – | 3444 |
|
|
2020
Q3 | $1.19M | Sell |
34,600
-29,460
| -46% | -$627K | 0.02% | 900 |
|
|
2020
Q2 | $1.07M | Buy |
+64,060
| New | +$1.09M | 0.02% | 906 |
|
|
2019
Q4 | – | Sell |
-55,278
| Closed | -$1.16M | – | 2951 |
|
|
2019
Q3 | $1.16M | Buy |
+55,278
| New | +$1.13M | 0.01% | 1131 |
|
|
2019
Q2 | – | Sell |
-13,800
| Closed | -$308K | – | 2790 |
|
|
2019
Q1 | $308K | Sell |
13,800
-14,288
| -51% | -$336K | ﹤0.01% | 1752 |
|
|
2018
Q4 | $672K | Sell |
28,088
-8,828
| -24% | -$228K | 0.01% | 1094 |
|
|
2018
Q3 | $1.01M | Buy |
36,916
+6,916
| +23% | +$196K | 0.01% | 983 |
|
|
2018
Q2 | $807K | Buy |
+30,000
| New | +$918K | 0.01% | 974 |
|
|
2018
Q1 | – | Sell |
-19,891
| Closed | -$752K | – | 2354 |
|
|
2017
Q4 | $752K | Buy |
+19,891
| New | +$642K | 0.01% | 961 |
|
Squarepoint's AIMT Position: Q4 2020 in Review
Squarepoint sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 34,600 shares — an estimated $1.19M sold.
Squarepoint first reported a position in AIMT in Q4 2017 and held it in 8 quarters. The position peaked at $1.19M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Squarepoint reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Squarepoint sold 34,600 Aimmune Therapeutics shares in Q4 2020, an estimated $1.19M.
- Squarepoint first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 8 quarters.
- Squarepoint's Aimmune Therapeutics position peaked at $1.19M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Squarepoint's 13F filing for Q4 2020, filed 16 Feb 2021.